Katanin P80 correlates with larger tumor size, lymph node metastasis, and advanced TNM stage and predicts poor prognosis in non–small‐cell lung cancer patients

Abstract

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. AbstractObjective: The present study aimed to investigate the correlation of katanin P80 expression with clinicopathological features and survival profile in non-small-cell lung cancer (NSCLC) patients. Methods:Totally, 398 NSCLC patients treated by pulmonary resection were enrolled and their tumor specimens were collected to determine katanin P80 expression by immunohistochemistry (IHC) assay. Clinical data were collected at diagnosis, and survival data including disease-free survival (DFS) and overall survival (OS) were assessed after treatment.Results: There were 195 (49.0%) patients with katanin P80 high expression and 203 (51.0%) patients with katanin P80 low expression, respectively. Meanwhile, katanin P80 high expression was associated with larger tumor size (P = .001), lymph node (LYN) metastasis (P = .005), and advanced TNM stage (P = .001). As for survival data, katanin P80 high expression was correlated with reduced DFS (P < .001) and OS (P < .001). And forward stepwise multivariate Cox's regression revealed that katanin P80 high expression was an independent predictor for decreased DFS (P < .001) and OS (P < .001). Besides, further analysis indicated that DFS (P < .001) and OS (P < .001) were the shortest in patients with katanin P80 high+++ expression, followed by patients with katanin P80 high++ expression and then those with katanin P80 high + expression and katanin P80 low expression. Conclusion:Katanin P80 correlates with larger tumor size, LYN metastasis, and advanced TNM stage, and serves as a potential biomarker for predicting poor survival in NSCLC patients. K E Y W O R D S disease-free survival, Katanin P80, non-small-cell lung cancer, overall survival, tumor features How to cite this article: Ye Q, Zhang M, Yin Y. Katanin P80 correlates with larger tumor size, lymph node metastasis, and advanced TNM stage and predicts poor prognosis in nonsmall-cell lung cancer patients. J Clin Lab Anal.

Katanin P60: a potential biomarker for lymph node metastasis and prognosis for non-small cell lung cancer

“…(3) As the cell proliferation was upregulated by katanin P60, the point mutations might be amplificated by increased number of genetic material duplication, which elevated the expression of tumor promotive genes such as TP53, MYC, and MET, and these genetic mutations might contribute to the development of chemoresistance and reduce the treatment response as well as survival outcomes in NSCLC patients [22]. Our findings were consistent with the previous study that katanin P80 correlates with larger tumor size, LYN metastasis, and advanced TNM stage and predicts poor survival in NSCLC patients [9]. Furthermore, there was a consistency between katanin P60 and katanin P80 expression in NSCLC, which was shown by our additional analysis (Supplementary Table 1, Supplementary Figure 2).…”

“…Previous studies mostly focus on the role of katanin in mitosis, meiosis, and microtubule release from centrosome in the neuron, whereas only a few of them investigate the implication of katanin in malignancies [5][6][7][8]. One existing study indicates that katanin P80 correlates with larger tumor size, lymph node (LYN) metastasis, and advanced TNM stage and serves as a potential biomarker for predicting poor survival in NSCLC patients [9]. As for katanin P60, it is initially identified to be aberrantly expressed in prostate cancer patients with bone metastasis, and upregulation of katanin P60 inhibits cell proliferation but enhances cell migration [10].…”

Katanin P60 and P80 in papillary thyroid carcinoma patients: Indicators for exacerbated tumor features and worse disease‐free survival

“…Katanin, a family of heterodimeric microtubule‐severing complex, regulates key cellular activities including cell division, migration, and differentiation through remodeling microtubule‐based structures, which consists of P60 subunit and P80 subunit 7 . Previous researches have illustrated that the aberrant expression of katanin P60 or katanin P80 participates in the development and progression of breast cancer, prostate cancer, and non–small‐cell lung cancer 8‐13 . For instance, katanin P60 represses cell proliferation while enhances cell migration in breast cancer; clinically, katanin P60 is associated with higher N stage, TNM stage and shorter overall survival (OS) in breast cancer patients 10,11 .…”

“…clinically, larger tumor size, lymph node metastasis, and advanced TNM stage were found in non-small-cell lung cancer patients with katanin P80 high expression compared to patients with katanin P80 low expression. 9,13 As for PTC, katanin P60 and P80 (katanin P60/ P80) induce mitotic spindle damage, which subsequently trigger chromosomal instability and participate in the tumorigenesis. 8,9,14 However, the clinical relevance of katanin P60/P80 in PTC patients is still unknown.…”

Clinical Significance of Polo-Like Kinase 4 as a Marker for Advanced Tumor Stage and Dismal Prognosis in Patients With Surgical Gastric Cancer

“…The IHC score ≤3 was defined as PLK4 low expression, and the IHC score >3 was defined as PLK4 high expression. 13 , 14 …”